DeepMed Research

Pegylated Recombinant Human Granulocyte Colony-stimulating Factor

Generic Name: Pegylated Recombinant Human Granulocyte Colony-stimulating Factor

Indication: ⑴非髓性恶性肿瘤患者在接受会发生有临床意义发热性中性粒细胞减少的抑制骨髓的抗肿瘤药治疗时，使用本品可降低发热性中性粒细胞减少引起的感染发生率。

⑵本品不用于造血干细胞移植的外周血祖细胞的动员。

Clinical Trials

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Phase 3

Recruiting

Conditions: Non-Hodgkin's Lymphoma
Hematopoietic Stem Cell Mobilization

Interventions: Drug: Etoposide
Combination Product: CHOP
Drug: Cytarabine
Combination Product: Hyper-CVAD
Combination Product: ID-MTX + Ara-C
Drug: PEG-rhG-CSF
Drug: G-CSF
Combination Product: DA-EPOCH
Combination Product: GDP
Combination Product: GDPE
Combination Product: ICE
Combination Product: DICE

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 99

Registration Number: NCT06520163

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China

and more 13 locations

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Phase 4

Recruiting

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: RhG-CSF

First Posted Date: 2023-09-07

Last Posted Date: 2023-09-07

Lead Sponsor: Chongqing University Cancer Hospital

Target Recruit Count: 174

Registration Number: NCT06026995

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China

The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization

Early Phase 1

Not yet recruiting

Conditions: Granulocyte Colony-Stimulating Factor

Interventions: Drug: PEG-rhG-CSF
Drug: G-CSF

First Posted Date: 2023-08-01

Last Posted Date: 2024-01-18

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 40

Registration Number: NCT05970185

Locations: 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Not Applicable

Not yet recruiting

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: RhG-CSF

First Posted Date: 2023-04-28

Last Posted Date: 2023-04-28

Lead Sponsor: Ou Bai, MD/PHD

Target Recruit Count: 144

Registration Number: NCT05834751

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Not Applicable

Recruiting

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: PEG-rhG-CSF

First Posted Date: 2022-09-10

Last Posted Date: 2024-03-19

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 68

Registration Number: NCT05536154

Locations: 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
Jinhua People's Hospital, Jinhua, Zhejiang, China
🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

and more 11 locations

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Not Applicable

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: PEG-rhG-CSF

First Posted Date: 2022-09-07

Last Posted Date: 2022-09-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 45

Registration Number: NCT05531279

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Not Applicable

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: PEG-rhG-CSF

First Posted Date: 2022-08-22

Last Posted Date: 2023-10-10

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 62

Registration Number: NCT05510089

Locations: 🇨🇳
Huzhou central hospital, Huzhou, Zhejiang, China
🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
The Affiliated People's Hospital of Ningbo University., Ningbo, Zhejiang, China

and more 9 locations

A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF

Phase 4

Not yet recruiting

Conditions: Granulocyte Colony-stimulating Factor
Stem Cell Mobilization

Interventions: Drug: PEG-rhG-CSF

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-16

Lead Sponsor: Ning Huang

Target Recruit Count: 80

Registration Number: NCT05409547

G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 1

Conditions: Granulocyte Colony-Stimulating Factor
PD-1 Inhibitor

Interventions: Drug: PEG-rhG-CSF

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 25

Registration Number: NCT05222009

Locations: 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Not Applicable

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: rhG-CSF

First Posted Date: 2021-12-14

Last Posted Date: 2021-12-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 80

Registration Number: NCT05156554

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy